This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.
Patients with histologically or radiologically confirmed metastatic liver cancer.
Age ≥ 18 years.
Patients who have voluntarily signed the informed consent form.
Patients with complete baseline clinical data.
Patients with primary liver cancer (e.g., hepatocellular carcinoma).
Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
Patients who have previously participated in other interventional clinical trials.
Patients with severe cognitive disorders or communication barriers that prevent informed consent.